Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel PPARG

Liyuan Zhou1,2, Shunhua Li1, Jing Ren1

  • 1Key Laboratory of Endocrinology of National Health Commission, Diabetes Research Center of Chinese Academy of Medical Sciences, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.

Insights

Familial partial lipodystrophy 3 (FPLD3) is linked to a novel PPARG mutation. A circRNA-miRNA-mRNA network in plasma exosomes reveals potential biomarkers and therapeutic targets for this rare genetic disorder.

Area of Science:

  • Genetics and Molecular Biology
  • Endocrinology and Metabolism

Background:

  • Familial partial lipodystrophy 3 (FPLD3) is a rare genetic disorder caused by PPARG mutations, leading to fat absence and metabolic issues.
  • The precise molecular mechanisms underlying FPLD3 pathogenesis remain incompletely understood.

Purpose of the Study:

  • To identify a novel genetic mutation in FPLD3 and elucidate the molecular mechanisms involved.
  • To investigate the role of circulating exosomal circRNA-miRNA-mRNA networks in FPLD3 pathophysiology.

Main Methods:

  • Recruited a Chinese FPLD3 family and performed genetic sequencing to identify mutations.
  • Utilized next-generation sequencing on plasma exosomes to analyze circRNAs, miRNAs, and mRNAs.
  • Conducted integration analysis and functional annotation to identify key regulatory networks and genes.

Main Results:

  • Identified a novel PPARG frameshift mutation (c.418dup: p.R140Kfs*7) in the FPLD3 patient.
  • Discovered significant alterations in 59 circRNAs, 57 miRNAs, and 299 mRNAs in mutation carriers.
  • Highlighted a circ_0001597-miR-671-5p-EGR1/AGPAT3 network involved in glucose and lipid metabolism.

Conclusions:

  • The novel PPARG mutation contributes to FPLD3 by disrupting metabolic regulation via an exosomal circRNA-miRNA-mRNA network.
  • Circ_0001597 may play a key role by sequestering miR-671-5p, affecting triglyceride synthesis and lipolysis through EGR1 and AGPAT3.
  • Findings suggest potential blood-based biomarkers and novel therapeutic strategies for FPLD3 and related metabolic disorders.